Berenberg analyst Luisa Hector raised the firm’s price target on AstraZeneca (AZN) to $97 from $93 and keeps a Buy rating on the shares. The firm increased its 2030 revenue forecast by 3% to $79B, ahead of consensus, saying the company has seen “substantial pipeline progress already this year.” AstraZeneca shares should price in a larger pipeline valuation, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Ondexxya Study: A Closer Look at Safety and Effectiveness
- AstraZeneca’s NASH Study Completes: Market Implications of AZD4831
- AstraZeneca’s Latest Study on Inhaler Propellants: Key Insights for Investors
- AstraZeneca’s Real-World Study on Dapagliflozin: A Strategic Move in Heart Failure Treatment
- AstraZeneca’s SERENA-1 Study: A Promising Development in Breast Cancer Treatment